-
HECOLCAP by
B2S - Biomime&c Bone Solu&ons
-
Team
Susana Sousa
Joo Cortez Fernando Monteiro
-
Bone infec6on, associated to: diabe6c foot ulcers; prostheses;
open fractures
8.5 million in USA & EU 150 million worldwide
SOURCE: Bonesupport; McNally, Lead Surgeon of the Bone Infec6on
Unit at the Nuffield Orthopaedic Centre in Oxford, UK
Osteomyeli3s
-
STANDARD TREATMENT
Surgery - 6ssue debridement
Intravenous an6bio6c administra6on
Final surgery for bone replacement
Treatment 6me N x 4-6 weeks
-
- Difficult to eradicate infec6on - Up to 40% recurrence and
high risk of amputaJon - Impaired long-term bone regeneraJon (at
least 6
months to regenerate)
- Prolonged hospital stay - Pa6ent pain and impaired
mobility
MAJOR ISSUES raised by specialists
-
NO EFFICIENT SOLUTION TO ERADICATE BONE INFECTION
AND ACTIVELY PROMOTE BONE REGENERATION
Eradica6on of infec6on Bone growth
An6bio6c effec6veness
Ac6ve bone regenera6on
-
HECOLCAP: the single intervenJon soluJon
-
Enables sustained, local delivery of an anJbioJc
AcJvely promotes bone regeneraJon
HECOLCAP: the single intervenJon soluJon
-
STANDARD TREATMENT
Surgery - 6ssue debridement
Intravenous an6bio6c administra6on
Final surgery for bone replacement
-
STANDARD TREATMENT
Surgery - 6ssue debridement
Intravenous an6bio6c administra6on
Final surgery for bone replacement
-
HECOLCAP
Surgery - 6ssue debridement
HECOLCAP applica6on SINGLE SURGERY
-
Bone growth Bone infec6on
-
Bone growth Bone infec6on
-
Bone growth
v v v v v v
Bone infec6on
-
Bone growth
v v v v v v
Bone infec6on
-
Bone growth
v v v
Bone infec6on
-
Bone growth Bone infec6on
-
Bone growth Bone infec6on
-
Bone growth Bone infec6on
HECOLCAP - local an6bio6c delivery, increasing its efficacy, and
ac6vely promotes bone regenera6on. All in a single interven6on.
-
PCT ApplicaJon WO2015162561 (A1)
Priority Date: 21.04.2014
COMPOSITION FOR LOCAL AND CONTROLLED RELEASE OF DRUGS AND
METHODS THEREOF
83%
17%
-
STANDARD TREATMENT COMPETITORS
CERAMENT & EluJBone
HECOLCAP
4 - 6 weeks 2 - 3 weeks 2 - 3 weeks
Parenteral an6bio6c administra6on Sustained local an6bio6c
delivery Sustained local an6bio6c delivery
High an6bio6c dose High local an6bio6c dose OpJmized anJbioJc
dose
- - AcJvely promotes bone regeneraJon
-
MarketTotal cases of OsteomyeliJs in the USA and Europe
8.5 million
65% 5.5 million USA
3 million Europe
CAGR 3.8% SOURCES: Bonesupport; McNally, Lead Surgeon of the
Bone Infec6on Unit at the Nuffield Orthopaedic Centre in Oxford
(UK)
-
MarketTotal cases of OsteomyeliJs in the USA and Europe
Acute OsteomyeliJts represent 10% of total cases
850 000 USA & Europe
Reten6on rate 95%
ca. 800 000 USA & Europe 8.5 million
65% 5.5 million USA
3 million Europe
CAGR 3.8% SOURCES: Bonesupport; McNally, Lead Surgeon of the
Bone Infec6on Unit at the Nuffield Orthopaedic Centre in Oxford
(UK)
-
Investment needs
1 2 3 4
Proof of concept
Years
100 k
Clinical studies
2.6M
TOTAL INVESTMENT 2.7 M
-
1 2 3 PRODUCT
DEVELOPMENT PRE MARKET APPROVAL
TRADE SELL
Exit Strategy
Johnson & Johnson Striker
Baxter Healthcare Velcura Therapeu6cs
-
Orthopedic surgeons now have a product that:
Op6mises an6bio6c delivery/dosage
Maximizes bone forma6on
Reduces overall treatment 6me and cost
HECOLCAP Single intervenJon soluJon for osteomyeliJs
-
HECOLCAP Single intervenJon soluJon for osteomyeliJs
G.B., Orthopedic Surgeon, Cleaveland Clinic, USA
... I believe this is the way forward. A soluAon such as this
would be really valuable for us.
